Press Releases
- Active Biotech's election committee appointed November 19, 2019 16:00 (CET)
- Active Biotech Interim report January – September 2019 November 14, 2019 08:30 (CET)Regulatory
- New preclinical data on naptumomab estafenatox will be presented at the Society for Immunotherapy of Cancer’s 34th Annual Meeting November 5, 2019 11:00 (CET)Regulatory
- Active Biotech and NeoTX today announce first patient dosed in the Phase 1b trial of naptumomab estafenatox in combination with durvalumab in solid tumors October 28, 2019 08:30 (CET)Regulatory
- Active Biotech: New data on laquinimod from the Phase 2 LEGATO-HD study in Huntington’s disease will be presented at the International congress of Parkinson’s disease and movement disorders September 23, 2019 08:30 (CEST)Regulatory
- Active Biotech AB: Interim report January – June 2019 August 8, 2019 08:30 (CEST)Regulatory
- Annual General Meeting of Active Biotech AB May 23, 2019 20:00 (CEST)Regulatory
- The Phase 2 LEGATO-HD study of laquinimod in Huntington's disease will be presented at the scientific conference "American Academy of Neurology - AAN" in Philadelphia, PA, on May 6 2019 May 3, 2019 13:00 (CEST)Regulatory
- The Election Committee of Active Biotech AB proposes Michael Shalmi to be appointed new Chairman of the Board and Uli Hacksell to be appointed new member of the Board May 2, 2019 13:00 (CEST)Regulatory
- Annual Report 2018 Active Biotech AB (publ) April 26, 2019 11:00 (CEST)Regulatory